Table 2.
Multivariate analysis for risk factors associated with CRS, PFS, and OS.
| Factors | Odds ratio (95% CI) | p-value | |||
|---|---|---|---|---|---|
| CRS | Grade 0–2 vs. Grade 3–4 | ||||
| Baseline SUV | 1.481 (1.030, 2.130) | 0.034 | |||
| Hazard ratio (95% CI) | |||||
| PFS after CAR-T cell therapy | |||||
| MTVE after CAR-T cell therapy | 1.001 (1.000, 1.002) | 0.041 | |||
| OS after CAR-T cell therapy | |||||
| No. of extra lymphadenopathy | 1.708 (1.101, 2.649) | 0.017 | |||
| Grade of CRS | 2.322 (1.046, 5.154) | 0.038 | |||
| SUVE after CAR-T cell therapy | 1.418 (1.029, 1.955) | 0.033 | |||
The data were described as hazard ratio (95% CI). The Cox regression model tests were used to test the p-values. (CRS, Cytokine release syndrome; PFS, Progression-free survival; OS, Overall survival; MTVE, early post therapy MTV; SUVE, early post therapy SUV).